disease interaction(s) of diabetes mellitus type-2 with steatosis (NAFLD, MASLD)
Jump to navigation
Jump to search
Management
- GLP-1 receptor agonist treatmment of diabetes mellitus type-2 lowers risk of steatosis progression to cirrhosis & mortality[1]
More general terms
References
- ↑ 1.0 1.1 Kanwal F et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med 2024 Sep 16; PMID: https://www.ncbi.nlm.nih.gov/pubmed/39283612 PMCID: PMC11406452 (available on 2025-09-16) https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2823685